PubRank

A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer

Clinical Trial ID NCT00620594

PubWeight™ 29.84‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00620594

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Akt and autophagy cooperate to promote survival of drug-resistant glioma. Sci Signal 2010 3.35
2 Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs. Oncotarget 2010 2.44
3 CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. Cancer Cell 2014 2.09
4 Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget 2012 1.96
5 Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica 2009 1.87
6 Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells. Cancer Biol Ther 2011 1.86
7 Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer. J Clin Oncol 2010 1.68
8 Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance. Cell Death Dis 2013 1.51
9 Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention. Oncotarget 2014 1.34
10 Current approaches and future directions in the treatment of HER2-positive breast cancer. Cancer Treat Rev 2012 1.23
11 Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer. Br J Cancer 2012 1.12
12 EGFR-TKI resistance in NSCLC patients: mechanisms and strategies. Am J Cancer Res 2014 1.08
13 Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer. Ann Oncol 2012 1.05
14 Combining mTOR Inhibitors with Chemotherapy and Other Targeted Therapies in Advanced Breast Cancer: Rationale, Clinical Experience, and Future Directions. Breast Cancer (Auckl) 2013 1.02
15 Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer. Biochim Biophys Acta 2014 0.96
16 Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies. Expert Rev Neurother 2009 0.95
17 Therapeutic targeting of cancers with loss of PTEN function. Curr Drug Targets 2014 0.93
18 Potential biofluid markers and treatment targets for renal cell carcinoma. Nat Rev Urol 2013 0.91
19 Utility of mTOR inhibition in hematologic malignancies. Oncologist 2011 0.88
20 When Standard Therapy Fails in Breast Cancer: Current and Future Options for HER2-Positive Disease. J Clin Trials 2013 0.78
21 Therapeutic advances in women's cancers. Front Biosci (Schol Ed) 2011 0.76
22 Personalized care in uterine cancer. Clin Adv Hematol Oncol 2012 0.76
Next 100